KOSDAQElectrical Equipment214610

RollingStone

₩2,290 0.00%2026-11-18 close
Market Cap
₩19.2B
Turnover
₩0
Volume
0 shares
Shares out.
8.4M
PER
—
PBR
1.9×
EPS
-₩2,875
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q1–2025Q4) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Fuel-led revenue, listing-review risk in focus

RollingStone's quarterly revenue stayed between KRW 27.9 billion and KRW 33.7 billion through 2026 and its losses narrowed each quarter, but most sales come from fuel and a trading halt and listing review have been in place since March 2026, so the earnings recovery and the institutional risk need to be read together.

  1. 1

    Revenue structure: the fuel segment accounted for about 99% of sales in Q2 2026, while the three diagnostics segments together represented roughly 1%.

  2. 2

    Earnings direction: the annual operating loss narrowed from KRW 25.9 billion in 2022 to KRW 9.94 billion in 2025, and quarterly operating losses narrowed from KRW 2.55 billion in Q1 2026 to KRW 1.33 billion in Q3 2026.

  3. 3

    Institutional risk: the audit opinion for fiscal 2025 was reported as a disclaimer caused by a scope limitation, and after the trading halt from March 23, 2026, the exchange set an improvement period running to April 10, 2027.

  4. 4

    Related-party funding: KRW 6 billion was lent to affiliate ID, equal to 15.07% of equity, with maturity on December 31, 2026.

  5. 5

    Cash flow: operating cash flow was negative in every year from 2022 to 2025, moving from -KRW 14 billion to -KRW 10.1 billion.

02

Business structure

RollingStone is an in-vitro diagnostics company founded in 2009 that listed on KOSDAQ in October 2020 and changed its name from THE BioMed in October 2025. Its disclosed business covers molecular diagnostics, immunodiagnostics and clinical chemistry products, along with diagnostic reagents and strips.

Its flagship lines include the VERI-Q PCR and nucleic acid extraction systems, cholesterol and hemoglobin monitors, and COVID-19 antigen test kits.

However, a product-level revenue breakdown compiled by WiseReport puts the fuel products segment at 98.67% of sales, leaving the diagnostics lines with a very small share of revenue. A Q2 2026 revenue breakdown also shows the fuel segment at 99%.

The 2025 domestic and export data lists kerosene, diesel and gasoline products as 100% domestic sales. Among diagnostic devices, the combined diagnostic analyzer and hemoglobin meter had a 63.14% export share in 2025, making it the main overseas-facing product.

In June 2026 the company signed an OEM and ODM agreement with China's HYSEN BIOTECH.

Its market sector is listed as electrical equipment, but the business confirmed in disclosures and company profiles is diagnostics and fuel sales, so its structure differs sharply from electrical equipment peers such as LS ELECTRIC and Hyosung Heavy Industries.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.7B-₩1.8B−106.4%
2025Q4———
2026Q1₩27.9B-₩2.6B−9.2%
2026Q2₩33.7B-₩1.7B−5.0%
2026Q3₩31.2B-₩1.3B−4.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩16.1B-₩25.9B-₩38.9B−160.8%−220.0%226.0%
2023₩5.4B-₩19.4B-₩25.8B−361.0%−69.8%68.8%
2024₩4.6B-₩19.2B—−414.5%—110.4%
2025₩10.9B-₩9.9B-₩24.1B−91.3%−151.2%59.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On the disclosed annual figures, revenue fell from KRW 16.1 billion in 2022 to KRW 5.37 billion in 2023 (down 66.7% year on year) and KRW 4.64 billion in 2024 (down 13.6%), then rebounded to KRW 10.9 billion in 2025 (up 134.6%). Revenue was largest in 2022 and smallest in 2024 across 2022 to 2025.

Operating losses were KRW 25.9 billion in 2022, KRW 19.4 billion in 2023, KRW 19.2 billion in 2024 and KRW 9.94 billion in 2025, a four-year run of losses in which the size of the loss narrowed each year.

The operating margin moved from -160.8% in 2022 to -361.0% in 2023 and -414.5% in 2024, then improved to -91.3% in 2025. In 2024, the year of smallest revenue, the operating loss of KRW 19.2 billion produced the worst margin in the period.

Net loss attributable to controlling shareholders was KRW 38.9 billion in 2022, KRW 25.8 billion in 2023 and KRW 24.1 billion in 2025, with no 2024 figure in the disclosures. Consolidated net loss including non-controlling interests was disclosed at the same amounts for those years.

The 2025 revenue rebound appears linked to the larger fuel share, but the precise drivers need to be confirmed in the annual report's segment information.

The balance sheet improved, with the debt-to-equity ratio falling from 226.0% in 2022 to 59.1% in 2025, and at year-end 2025 total equity was KRW 15.9 billion against total liabilities of KRW 9.42 billion.

Operating cash flow was negative every year, at -KRW 14 billion in 2022, -KRW 11.4 billion in 2023, -KRW 10.7 billion in 2024 and -KRW 10.1 billion in 2025.

Quarterly revenue in 2026 was KRW 27.9 billion in Q1, KRW 33.7 billion in Q2 (up 20.8% from the prior quarter) and KRW 31.2 billion in Q3 (down 7.3% quarter on quarter and up 1,784.8% year on year). Q1 2026 revenue already exceeded full-year 2025 revenue of KRW 10.9 billion.

Operating losses were KRW 2.55 billion, KRW 1.68 billion and KRW 1.33 billion in Q1 to Q3 2026, three consecutive quarters of losses that narrowed each quarter, and net losses attributable to controlling shareholders were KRW 2.71 billion, KRW 1.9 billion and KRW 1.13 billion over the same quarters.

The net loss attributable to controlling shareholders over the four quarters of 2025 totaled KRW 24.1 billion. Separately, the fiscal 2025 audit opinion was reported as a disclaimer caused by a scope limitation, so the 2025 figures should be read alongside that open issue. Share capital also changed through a free capital reduction and third-party rights offerings during 2025.

05

Industry analysis

Although classified under electrical equipment, RollingStone's actual revenue source is fuel sales, so the drivers of its earnings are the trading structure of fuel distribution and the restructuring of its diagnostics business rather than the power equipment cycle.

Fuel distribution generally carries thin margins relative to sales, which fits the pattern of a 2025 revenue rebound to KRW 10.9 billion that still left an operating loss.

In in-vitro diagnostics, RollingStone appears to be a small company with molecular diagnostics devices and immunochemistry and clinical chemistry products, and its scale and distribution reach are smaller than those of large diagnostics makers.

Demand for diagnostic devices and reagents depends on hospital and laboratory purchasing and on overseas distribution partners. Its export-heavy products, such as the diagnostic analyzer and the hemoglobin meter, expose it to overseas demand and exchange rates.

Peers in the electrical equipment group such as LS ELECTRIC, Hyosung Heavy Industries and HD Hyundai Electric move with power infrastructure investment, so averaging their metrics against RollingStone would mix companies with different business structures.

The most practical evidence of cycle position will be the segment revenue and operating profit in the next annual report, and comparisons with the sector become meaningful once that segment data is available.

06

Outlook

At the March 31, 2026 annual general meeting, shareholders approved a partial amendment to the articles, and the company said the change removes business purposes it no longer pursues. The same meeting approved legal action, including a provisional injunction application to block delisting procedures.

The company filed an objection to its delisting review, and the exchange granted an improvement period running to April 10, 2027, during which the trading halt continues according to reports.

The improvement period is tied to the statutory deadline for the next annual report, and the company must submit an implementation record and an expert confirmation. In April 2026 the board resolved to buy back KRW 5 billion of convertible bonds over the counter before maturity.

Employees were granted stock options over 978,320 shares, exercisable from March 31, 2028 to March 30, 2031. The KRW 6 billion loan to affiliate ID carries a 5% interest rate and matures on December 31, 2026, secured by a second-ranking pledge of KRW 7.2 billion on a property owned by ID.

The largest shareholder, JB Asset Management, was reported to hold 38.56%.

The next confirmation point is the 2026 annual report, which will be the first disclosure of Q4 2026 results, along with whether the fuel share stays high, whether the operating loss keeps narrowing in Q4, and whether the audit opinion issue is resolved.

07

Valuation

PER
—
PBR
1.9×
ROE
-133.5%
EPS
-₩2,875
BPS
₩1,229
Dividend per share
₩0

Because the net loss attributable to controlling shareholders over the last four quarters totaled KRW 24.1 billion, an earnings-based price multiple cannot be calculated. The price-to-book ratio sits above 1 times, meaning the share price is set above book equity.

Total equity was KRW 15.9 billion at year-end 2025 after a run of losses, so the same multiple means different things depending on how much equity could still erode. There is no cash dividend history, so a dividend-based comparison does not apply.

The 2025 free capital reduction and third-party rights offerings, along with the 2026 stock option grant, changed the share count, so per-share measures should be compared with the past only after adjusting for those changes.

After the March 23, 2026 trading halt, it is worth checking whether the share price reflects normal trading flows.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Larger revenue base

Quarterly revenue in 2026 was KRW 27.9 billion in Q1, KRW 33.7 billion in Q2 and KRW 31.2 billion in Q3, well above full-year 2025 revenue of KRW 10.9 billion. Q3 2026 revenue rose 1,784.8% year on year. A larger revenue base gives room to spread fixed costs, which is the starting point for an earnings recovery.

Losses narrowing each quarter

Operating losses narrowed from KRW 2.55 billion in Q1 2026 to KRW 1.68 billion in Q2 and KRW 1.33 billion in Q3. Net losses attributable to controlling shareholders followed the same path, from KRW 2.71 billion to KRW 1.9 billion and KRW 1.13 billion. Losses continued for three quarters, but the direction has been narrowing.

Improved financial structure

The debt-to-equity ratio fell from 110.4% in 2024 to 59.1% in 2025. Total equity at year-end 2025 was KRW 15.9 billion and total liabilities were KRW 9.42 billion. The operating margin improved from -414.5% in 2024 to -91.3% in 2025, so the intensity of the loss structure has eased.

09

Bear factors

Four years of losses and negative cash flow

Operating losses ran for four consecutive years, from KRW 25.9 billion in 2022 to KRW 9.94 billion in 2025. Operating cash flow was negative in every year, from -KRW 14 billion to -KRW 10.1 billion. Even with smaller losses, the disclosed figures do not yet show cash generation from core operations.

Trading halt and delisting review

Trading was halted on March 23, 2026, and the fiscal 2025 audit opinion was reported as a disclaimer caused by a scope limitation. The company filed an objection, and the exchange granted an improvement period through April 10, 2027. The timing of trading resumption and the outcome for the listing remain uncertain.

Related-party funding and ownership

KRW 6 billion was lent to affiliate ID at 5%, equal to 15.07% of equity, secured by a second-ranking pledge of KRW 7.2 billion on a property owned by ID. The largest shareholder disclosed that it borrowed from IID to fund its share of a rights offering. Funds moving between related parties require ongoing monitoring.

10

Risk factors

Listing-status risk

The exchange set an improvement period through April 10, 2027. If the company cannot submit implementation results within that window, a delisting decision follows. The period could change with an extension of the annual report deadline or an approved exemption from sanctions. A prolonged halt increases the liquidity risk of the shares.

Audit and disclosure reliability

The fiscal 2025 audit opinion was reported as a disclaimer caused by a scope limitation, meaning the auditor could not obtain enough evidence for an opinion. The 2025 figures should be read with this open issue in mind. If the opinion is not resolved, the 2026 annual report faces the same question about reliability.

Related-party and dilution risk

The KRW 6 billion affiliate loan matures on December 31, 2026 and carries 5% interest. Stock options over 978,320 shares granted to employees would add to the share count if exercised.

The board resolved in April 2026 to buy back KRW 5 billion of convertible bonds, reducing one source of potential dilution, while rights offerings and a free capital reduction also took place during 2025.

11

What to watch next

  1. December 31, 2026

    Maturity of the KRW 6 billion loan to affiliate ID. Whether principal and interest are repaid, and how, is the checkpoint for related-party funding flows.

  2. End of March 2027 (statutory deadline for the annual report)

    The 2026 annual report will disclose Q4 and full-year 2026 results together with the audit opinion. The checkpoints are whether the 2025 audit issue is resolved and whether the operating loss kept narrowing in Q4.

  3. April 10, 2027

    End of the improvement period granted by the exchange. Implementation results, the delisting decision and whether the trading halt continues will be determined around this date.

  4. Mid-May 2027

    Filing of the Q1 2027 quarterly report. The checkpoints are whether quarterly revenue holds near the 2026 levels of KRW 27.9 billion, KRW 33.7 billion and KRW 31.2 billion, and whether the fuel share remains high.

12

Overall view

RollingStone recorded operating losses in each year from 2022 to 2025 and negative operating cash flow over the same period, but its operating margin improved from -160.8% in 2022 to -91.3% in 2025.

Quarterly revenue in 2026 rose to KRW 27.9 billion, KRW 33.7 billion and KRW 31.2 billion, and operating and controlling-shareholder net losses narrowed over three consecutive quarters.

Most sales, however, come from the fuel segment, with diagnostics at roughly 1% of revenue, so whether this shift reflects a recovery in the core business is still difficult to judge.

On the institutional side, the March 23, 2026 trading halt, the reported disclaimer on the fiscal 2025 audit opinion and the improvement period through April 10, 2027 overlap, making the listing outcome the largest variable.

The KRW 6 billion related-party loan and the pledge-backed borrowing by the largest shareholder also need to be followed. The next checkpoints are the loan maturity on December 31, 2026, the 2026 annual report and its audit opinion, and the end of the improvement period on April 10, 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. butler.works
  2. comp.wisereport.co.kr
  3. topstarnews.net
  4. m.news.nate.com
  5. news.nate.com
  6. tipranks.com
  7. investing.com
  8. news.nate.com
  9. news.nate.com
  10. m.news.nate.com
  11. m.news.nate.com
  12. rollingstone.com
  13. news.nate.com
  14. m.news.nate.com
  15. m.news.nate.com
  16. m.news.nate.com
  17. goinsider.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis